证券代码：300006 证券简称：莱美药业 公告编号：2025-059 重庆莱美药业股份有限公司 关于持股 5%以上股东所持部分股份被司法执行 被动减持的提示性公告 公司持股 5%以上股东邱宇保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、重庆莱美药业股份有限公司（以下简称"公司"）持股 5%以上股东邱宇 （持有公司股份 110,700,054 股，占公司总股本的 10.48%）因与国海证券股份有 限公司（以下简称"国海证券"）开展质押式证券回购业务相关债务逾期，国海 证券拟依据广西壮族自治区南宁市青秀区人民法院出具的《协助执行通知书》， 将通过集中竞价方式继续处置邱宇持有的 54 股公司股份。本次减持计划自本公 告披露之日后的 3 个月内进行，且任意连续 90 个自然日内通过集中竞价交易减 持股份的总数不超过公司股份总数的 1%。 2、股东邱宇本次被动减持的股票于 2017 年 8 月 23 日办理了股票质押式回 购业务，系在 2023 年 8 月 27 日前已被质押并办理了质押登记。股东 ...

Core Viewpoint - The company has completed the technical design for the overseas expansion of Canalin and has entered the preclinical animal testing phase [1] Group 1: Company Developments - The company has conducted substantial equivalent scheme research and small-scale process work related to the overseas expansion of Canalin [1] - The company plans to advance its overseas market expansion in phases based on actual business planning and product conditions [1]

Group 1 - The core point of the article is that Laimei Pharmaceutical (300006) reported a total of 31,490 shareholders as of December 10, 2025 [1]

Core Viewpoint - Laimei Pharmaceutical reported a decrease in the number of shareholders and a decline in financial performance for the third quarter, indicating potential challenges for the company moving forward [2] Shareholder Information - As of December 10, the number of shareholders for Laimei Pharmaceutical was 31,490, a decrease of 1,813 from the previous period (November 30), representing a month-on-month decline of 5.44% [2] Stock Performance - The closing price of Laimei Pharmaceutical was 4.86 yuan, reflecting an increase of 1.67%. However, since the concentration of shares began, the stock price has cumulatively decreased by 5.63%, with 4 days of increases and 6 days of decreases during this period [2] Financial Performance - For the first three quarters, Laimei Pharmaceutical achieved a total operating revenue of 581 million yuan, a year-on-year decrease of 4.06%. The net profit was -45.9172 million yuan, representing a year-on-year decline of 73.82%. The basic earnings per share were -0.0435 yuan [2]

Group 1 - The core point of the article is that Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration [2] Group 2 - The medical device registration certificates were issued to Hainan Laimei Medical Devices Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical [2] - This development indicates a positive regulatory milestone for the company in the medical device sector [2] - The announcement was made on the evening of December 10 [2]

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

Core Viewpoint - Laimei Pharmaceutical (300006.SZ) announced that its subsidiary, Hainan Laimei Medical Equipment Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for a medical electronic endoscope image processor and an electronic bronchoscope [1] Group 1 - The company has received regulatory approval for two new medical devices, indicating progress in its product development and regulatory compliance [1] - The registered products include a medical electronic endoscope image processor and an electronic bronchoscope, which are significant for the medical imaging and respiratory care sectors [1]

Core Viewpoint - Laimei Pharmaceutical announced that its subsidiary, Hainan Laimei Medical Devices, received two medical device registration certificates from the Hainan Provincial Drug Administration for a medical electronic endoscope image processor and an electronic bronchoscope [1] Group 1 - The company has received regulatory approval for two new medical devices [1] - The products include a medical electronic endoscope image processor and an electronic bronchoscope [1]

Core Viewpoint - Laimei Pharmaceutical (300006.SZ) announced that its subsidiary, Hainan Laimei Medical Devices Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its electronic endoscope image processor and electronic bronchoscope, enhancing its product offerings and competitive edge in the medical device market [1] Group 1 - The subsidiary received certification for two medical devices, which are the electronic endoscope image processor and electronic bronchoscope [1] - These products allow direct observation of patient images, aiding in clinical diagnosis and treatment [1] - The certification will diversify the company's medical device product range and meet market demand, positively impacting future operations [1]

南财智讯12月10日电，莱美药业公告，公司控股子公司海南莱美医疗器械有限公司收到海南省药品监督 管理局颁发的两项《医疗器械注册证》。医用电子内窥镜图像处理器（型号：TS-02）与电子支气管镜 （型号：LM-01）分别获准注册，有效期均为2025年11月17日至2030年11月16日。前者适用于与电子支 气管镜配套使用，处理并显示内窥镜图像；后者适用于在气管和支气管的检查与治疗中提供视频影像。 上述产品获证将丰富公司医疗器械产品种类，提升公司综合竞争力，对公司未来经营产生积极影响。实 际销售情况取决于市场推广效果，目前尚无法预测其对公司未来业绩的具体影响。 ...